Caisse DE Depot ET Placement DU Quebec Acquires 59,169 Shares of DaVita Inc. (NYSE:DVA)

Caisse DE Depot ET Placement DU Quebec boosted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 533.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,269 shares of the company's stock after acquiring an additional 59,169 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.09% of DaVita worth $10,509,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Tidal Investments LLC boosted its holdings in DaVita by 45.2% during the third quarter. Tidal Investments LLC now owns 5,688 shares of the company's stock worth $932,000 after buying an additional 1,771 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of DaVita by 134.6% during the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of DaVita by 20.7% in the fourth quarter. GAMMA Investing LLC now owns 1,587 shares of the company's stock worth $237,000 after buying an additional 272 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of DaVita by 4.9% in the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after purchasing an additional 12,339 shares during the period. Institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DVA shares. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Barclays upped their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. Finally, Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $166.33.

DaVita Stock Up 0.9 %

NYSE DVA traded up $1.29 during trading hours on Wednesday, reaching $143.91. 674,067 shares of the company's stock were exchanged, compared to its average volume of 819,640. The company has a market capitalization of $11.06 billion, a price-to-earnings ratio of 13.40, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company's 50-day moving average is $145.88 and its two-hundred day moving average is $154.27. DaVita Inc. has a one year low of $131.44 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.